Papers

2

Total Citations

174

H-Index

2

About

Dr. Chloe Friedman is a leading surgical oncologist whose research focuses on optimizing outcomes for patients undergoing complex gastrointestinal cancer surgeries. Her work critically examines the real-world effectiveness of minimally invasive techniques, particularly for pancreatic and esophageal cancers. Dr. Friedman’s most influential study, with over 159 citations, rigorously compared minimally invasive pancreaticoduodenectomy (MIPD) to the traditional open approach using the National Cancer Database. This landmark analysis revealed that the benefits of MIPD are highly dependent on hospital volume, providing crucial evidence for surgical decision-making and patient referral patterns. In a subsequent study, she demonstrated that conversion from a minimally invasive to an open esophagectomy is associated with significantly worse short-term outcomes, highlighting the importance of patient selection and surgical expertise. By leveraging large national datasets, Dr. Friedman provides actionable insights that bridge the gap between clinical trial findings and real-world surgical practice, directly impacting how high-risk cancer surgeries are performed and evaluated.

Research Focus

Key Achievements

2
H-Index
2
Papers
174
Total Citations
87
Avg Citations/Paper
🏆 Most Cited Paper
Comparing Short-term and Oncologic Outcomes of Minimally Invasive Versus Open Pancreaticoduodenectomy Across Low and High Volume Centers
159 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: University of Colorado Anschutz Medical Campus, University of Colorado Denver

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago